| Aug 6 |
How These Two Lesser-Known Biotech Names Obliterated Sales Expectations
|
| Aug 6 |
Halozyme Therapeutics: Q2 Earnings Snapshot
|
| Aug 6 |
Halozyme Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook
|
| Aug 6 |
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
|
| Aug 6 |
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
|
| Aug 5 |
Halozyme Therapeutics Q2 2024 Earnings Preview
|
| Aug 5 |
Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics
|
| Aug 2 |
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
|
| Jul 31 |
J&J wins another FDA label expansion for multiple myeloma therapy
|
| Jul 30 |
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
